This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Stiripentol in Dravet Syndrome

Expanded access is no longer available for this treatment.
Information provided by (Responsible Party):
Elaine C. Wirrell, Mayo Clinic Identifier:
First received: February 9, 2012
Last updated: February 26, 2013
Last verified: February 2013
The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

Condition Intervention
Dravet Syndrome Drug: stiripentol

Study Type: Expanded Access     What is Expanded Access?
Official Title: Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome

Resource links provided by NLM:

Further study details as provided by Elaine C. Wirrell, Mayo Clinic:

Study Start Date: February 2012
Estimated Study Completion Date: February 2013
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: stiripentol
    Stiripentol up to 30 mg/kg/day to control seizures
    Other Name: Diacomit

Ages Eligible for Study:   11 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01533506

United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Elaine Wirrell, MD Mayo Clinic
  More Information

Responsible Party: Elaine C. Wirrell, Consultant, Mayo Clinic Identifier: NCT01533506     History of Changes
Other Study ID Numbers: 12-000690
Study First Received: February 9, 2012
Last Updated: February 26, 2013

Keywords provided by Elaine C. Wirrell, Mayo Clinic:
treatment with stiripentol

Additional relevant MeSH terms:
Epilepsies, Myoclonic
Pathologic Processes
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Anticonvulsants processed this record on September 19, 2017